Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 8, Issue 17
September 10 2024
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Myo1c drives actin-dependent VWF expulsion from EC WPBs
Luiza Rusu,Richard D. Minshall
View Articletitled, Myo1c drives actin-dependent VWF expulsion from EC WPBs
A boost for poor graft function
Clinical Trials & Observations
Mohamad Mohty,Florent Malard
View Articletitled, A boost for poor graft function
Prophylactic VSTs: a promising start but still work to do
Clinical Trials & Observations
Caitlin W. Elgarten,Michael Grimley
View Articletitled, Prophylactic VSTs: a promising start but still work to do

DRUG ADVANCES

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas
Clinical Trials & Observations
J. Erika Haydu,Jeremy S. Abramson
View Articletitled, The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas

CLINICAL TRIALS AND OBSERVATIONS

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
Clinical Trials & Observations
Aaron T. Gerds,Claire Harrison,Jean-Jacques Kiladjian,Ruben Mesa,Alessandro M. Vannucchi,Rami Komrokji,Prithviraj Bose,Marina Kremyanskaya,Adam J. Mead,Jason Gotlib,Shelonitda Rose,Fabian Sanabria,Niloufar Marsousi,Ana Carolina Giuseppi,Huijing Jiang,Jeanne M. Palmer,Kelly McCaul,Vincent Ribrag,Francesco Passamonti
View Articletitled, Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
Supplemental data
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
Clinical Trials & Observations
Michael Wang,Tadeusz Robak,Kami J. Maddocks,Tycel Phillips,Stephen D. Smith,David Gallinson,Roser Calvo,Chuan-Chuan Wun,Veerendra Munugalavadla,Wojciech Jurczak
View Articletitled, Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
Supplemental data
COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study
Clinical Trials & Observations
Alan R. Anderson,John J. Strouse,Deepa Manwani,Amanda M. Brandow,Elliott Vichinsky,Andrew Campbell,Patrick J. Leavey,Alecia Nero,Ibrahim F. Ibrahim,Joshua J. Field,Amanda Baer,Haideliza Soto-Calderon,Lauren Vincent,Yan Zhao,Jefferson J. S. Santos,Scott E. Hensley,Nicole Mortier,Sophie Lanzkron,Donna Neuberg,Charles S. Abrams,on behalf of the investigators of the American Society of Hematology Research Collaborative Sickle Cell Disease Research Network
View Articletitled, COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Clinical Trials & Observations
Thomas Witzig,Lubomir Sokol,Won Seog Kim,Fátima de la Cruz Vicente,Alejandro Martín García-Sancho,Ranjana Advani,Jose Maria Roncero Vidal,Raquel de Oña Navarrete,Ana Marín-Niebla,Antonia Rodriguez Izquierdo,María José Terol,Eva Domingo-Domenech,Andrew Saunders,Nawal Bendris,Julie Mackey,Mollie Leoni,Francine Foss
View Articletitled, Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Supplemental data
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival
Clinical Trials & Observations
Roman M. Shapiro,Haesook T. Kim,Remy Dulery,Deborah Liney,Heather M. Garrity,Kevin Panaro,Chloe Au,Casey Gervais,Jessica S. Little,Vincent T. Ho,Corey S. Cutler,John Koreth,Mahasweta Gooptu,Joseph H. Antin,Amar H. Kelkar,Rizwan Romee,Catherine J. Wu,Jerome Ritz,Robert J. Soiffer,Sarah Nikiforow
View Articletitled, Active infection at the time of CD34<sup>+</sup> selected stem cell boost is associated with treatment failure and poor overall survival
Supplemental data
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
Clinical Trials & Observations
Sanjeet S. Dadwal,Rajat Bansal,Michael W. Schuster,Jean A. Yared,Gary Douglas Myers,Michelle Matzko,Sama Adnan,David McNeel,Julie Ma,Sarah A. Gilmore,Spyridoula Vasileiou,Ann M. Leen,Joshua A. Hill,Jo-Anne H. Young
View Articletitled, Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
Supplemental data

GENE THERAPY

Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A
Clinical Trials & Observations
Suresh Agarwal,Krystal Sandza,Kristin Obrochta Moss,Monica Vora,Alisa Bowen,Brenna Bunch,Jennifer Holcomb,Tara M. Robinson,Kala Jayaram,Chris B. Russell,Stephen Zoog,Christian Vettermann,Joshua Henshaw
View Articletitled, Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A

HEALTH SERVICES AND OUTCOMES

Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma
Abi Vijenthira,Andrew Calzavara,Chenthila Nagamuthu,Yosuf Kaliwal,Ning Liu,Danielle Blunt,Shabbir Alibhai,Anca Prica,Matthew C. Cheung,Lee Mozessohn
View Articletitled, Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells
Jaco A. C. van Bruggen,Fleur S. Peters,Morris Mes,Joanne M. Rietveld,Elisa Cerretani,Gaspard Cretenet,Roel van Kampen,Aldo Jongejan,Perry D. Moerland,J. Joseph Melenhorst,Gerritje J. W. van der Windt,Eric Eldering,Arnon P. Kater
View Articletitled, T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells
Supplemental data

Frailty and clinical outcomes by age

Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Nilesh M. Kalariya,Michelle A. T. Hildebrandt,Doris K. Hansen,Surbhi Sidana,Jack Khouri,Christopher J. Ferreri,William N. Doyle,Omar Castaneda-Puglianini,Ciara L. Freeman,Vanna Hovanky,Hitomi Hosoya,Leyla O. Shune,Krina K. Patel
View Articletitled, Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Supplemental data

LYMPHOID NEOPLASIA

Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib
Clinical Trials & Observations
Burcu Aslan,Ganiraju Manyam,Lakesla R. Iles,Shady I. Tantawy,Sai Prasad Desikan,William G. Wierda,Varsha Gandhi
View Articletitled, Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib
Supplemental data

MYELOID NEOPLASIA

Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020
Hanhua Liu,Simon J. Stanworth,Sean McPhail,Mark Bishton,Brian Rous,Andrew Bacon,Thomas Coats
View Articletitled, Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020
Supplemental data
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML
Julien M. P. Grenier,Céline Testut,Matthieu Bal,Florence Bardin,Maria De Grandis,Véronique Gelsi-Boyer,Julien Vernerey,Marjorie Delahaye,Samuel Granjeaud,Christophe Zemmour,Jean-François Spinella,Triantafyllos Chavakis,Stéphane J. C. Mancini,Jean-Marie Boher,Josée Hébert,Guy Sauvageau,Norbert Vey,Jürg Schwaller,Marie-Anne Hospital,Cyril Fauriat,Michel Aurrand-Lions
View Articletitled, Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML
Supplemental data

PLATELETS AND THROMBOPOIESIS

Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience
Alice Taylor,Louisa Keogh,Emmy Dickens,Tina Dutt,John Grainger,Rennick Gregory,Claire Mapplebeck,Michael Richards,Simone Stokley,Styliani Salta,Thomas Taylor,Marie Scully
View Articletitled, Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience

THROMBOSIS AND HEMOSTASIS

Myosin-1C augments endothelial secretion of von Willebrand factor by linking contractile actomyosin machinery to the plasma membrane
Sammy El-Mansi,Tom P. Mitchell,Golzar Mobayen,Thomas A. J. McKinnon,Pika Miklavc,Manfred Frick,Thomas D. Nightingale
View Articletitled, Myosin-1C augments endothelial secretion of von Willebrand factor by linking contractile actomyosin machinery to the plasma membrane
Supplemental data

TRANSFUSION MEDICINE

Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients
Aaron B. Boothby,Matthew K. Tanner,Abdullah Alswied,Danny Youngs,Josefine Bribiesca Rodriguez,Thejaswi Bikkani,Nuri Cha,Terry Gernsheimer,Idoia Gimferrer,John R. Hess,Lauge Sokol-Hessner,Snigdha Marivada,Michael G. Nash,Willy A. Flegel,Ralph R. Vassallo,David F. Stroncek,Hamilton C. Tsang,Sandhya R. Panch
View Articletitled, Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients
Supplemental data

TRANSPLANTATION

Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation
John S. Riley,Cara L. Berkowitz,Valerie L. Luks,Apeksha Dave,Mojisola C. Cyril-Olutayo,Jennifer Pogoriler,Alan W. Flake,Osheiza Abdulmalik,William H Peranteau
View Articletitled, Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation
Supplemental data
CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation
Danniel Zamora,Hu Xie,Alicja Sadowska-Klasa,Eleftheria Kampouri,Melinda A. Biernacki,Masumi Ueda Oshima,Elizabeth Duke,Margaret L. Green,Louise E. Kimball,Leona Holmberg,Alpana Waghmare,Alexander L. Greninger,Keith R. Jerome,Geoffrey R. Hill,Joshua A. Hill,Wendy M. Leisenring,Michael J. Boeckh
View Articletitled, CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation
Supplemental data
Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation
Joseph A. Pidala,Lynn Onstad,Emily Baumrin,Paul A. Carpenter,Corey Cutler,Sally Arai,Carrie L. Kitko,George L. Chen,Stephanie J. Lee
View Articletitled, Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation
Supplemental data

RESEARCH LETTERS

Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation
Stephen P. Persaud,Aditya R. Yelamali,Julie K. Ritchey,John F. DiPersio
View Articletitled, Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation
Supplemental data
In utero hematopoietic stem cell transplantation for Fanconi anemia
Leah Swartzrock,Carla Dib,Morgane Denis,Hana Willner,Katie Ho,Ethan Haslett,Jian Han,Wenjing Pan,Miranda Byrne-Steele,Brittany Brown,Mark R. Krampf,Anna Girsen,Yair J. Blumenfeld,Yasser Y. El-Sayed,Maria G. Roncarolo,Tippi C. MacKenzie,Agnieszka D. Czechowicz
View Articletitled, In utero hematopoietic stem cell transplantation for Fanconi anemia
Supplemental data
Transformation of marginal zone lymphoma to Hodgkin lymphoma
Kamilia N. Moalem,Juan Pablo Alderuccio,Côme Bommier,Thomas Habermann,Brian K. Link,James R. Cerhan,Jorge Florindez,Izidore S. Lossos
View Articletitled, Transformation of marginal zone lymphoma to Hodgkin lymphoma
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals
Warren B. Fingrut,James Troyer,Eddrika Russell,Melanie Aviles,Sherraine Della-Moretta,Dre’Von Dobson,Zainul Hasanali,Bei Hu,Ajibike Lapite,Pallavi M. Pillai,Joseph W. Schramm,Lynda M. Villagomez,Phuong Vo,Ruth Wang’ondu,Jennifer Yui,Angela C. Weyand
View Articletitled, The American Society of Hematology Health Equity Compendium: examining health equity across the <em>Blood</em> journals
Supplemental data
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia
Andrew Palmer,Garth Rauscher,Ivy Abraham,Madelyn Burkart,Ami Dave,Nepheli Raptis,Ahmed Aleem,Vedavyas Gannamani,Amani Erra,Sarah Monick,Carlos Galvez,Syed Shah,Hamed Rahmani Youshanlouei,Melissa L. Larson,Maryam Zia,Stephanie B. Tsai,Jessica K. Altman,Wendy Stock,Irum Khan,Anand A. Patel
View Articletitled, Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia
Supplemental data
A budget impact analysis of gene therapy for sickle cell disease: an updated analysis
Patrick C. DeMartino,Meredith B. Haag,Aaron B. Caughey,Joshua A. Roth
View Articletitled, A budget impact analysis of gene therapy for sickle cell disease: an updated analysis
Supplemental data

ERRATUM

Joseph JM, Hillengass J, Tang L, et al. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population. Blood Adv. 2024;8(3):538-548.
View Articletitled, Joseph JM, Hillengass J, Tang L, et al. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population. <em>Blood Adv.</em> 2024;8(3):538-548.
  • Cover Image

    Cover Image

    issue cover

    (Top) Illustration of a bispecific antibody (yellow and orange) binding to 2 different membrane proteins (purple and blue). Source: Thom Leach/Science Photo Library. (Bottom) Chimeric antigen receptor T-cell immunotherapy. Source: luismmolina/istock.

All Issues

Advertisement intended for health care professionals

Histiocytosis of the orbit and its association with KRAS mutations
NUP98 is rearranged in 5.0% of adult East Asian patients with AML
Addressing financial hardship in malignant hematology and hematopoietic cell transplant: a team approach
CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals